RLYB
Rallybio Corp

629
Mkt Cap
$25.08M
Volume
31,805.00
52W High
$6.99
52W Low
$1.76
PE Ratio
-1.86
RLYB Fundamentals
Price
$4.72
Prev Close
$4.75
Open
$4.59
50D MA
$5.49
Beta
1.45
Avg. Volume
18,111.44
EPS (Annual)
-$10.61
P/B
0.40
Rev/Employee
$25,440.00
Loading...
Loading...
News
all
press releases
News Placeholder
Rallybio Announces Reverse Stock Split of Common Stock
Rallybio Corporation (Nasdaq: RLYB) will effect a one-for-eight reverse stock split of its issued and outstanding common stock. Stockholders of Rallybio approved an amendment to Rallybios Amended and...
Business Wire·6d ago
News Placeholder
Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today reported...
Business Wire·3mo ago
News Placeholder
RXRX Stock Up on Acquiring Full Rights to the Hypophosphatasia Program
Recursion Pharmaceuticals stock jumps after securing full rights to REV102, aiming to fast-track the first oral therapy for hypophosphatasia.
Zacks·7mo ago
<
...
1
>

Latest RLYB News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.